Welcome to our dedicated page for Lantern Pharma news (Ticker: LTRN), a resource for investors and traders seeking the latest updates and insights on Lantern Pharma stock.
Lantern Pharma Inc. (Symbol: LTRN) is at the forefront of innovation in the realm of cancer treatment, striving to deliver the most effective therapies to patients who are poised to benefit the most. The company employs a pioneering precision medicine approach to cancer treatment, leveraging biomarker-based genetic screening to identify and treat patients who would derive the greatest benefit from their drugs. This method not only reduces the cost of drug development but also expedites the time to market.
Lantern Pharma's core business revolves around its proprietary artificial intelligence (AI) and machine learning (ML) platform, RADR. The RADR platform assimilates oncology-focused data points and utilizes advanced ML algorithms to address complex, billion-dollar challenges in cancer drug development. This innovative platform has significantly accelerated the company's growing pipeline of precision therapies, with input from world-class scientific advisors and collaborators.
In addition to its in-house development, Lantern Pharma adopts a strategic approach by acquiring or partnering with promising drug and diagnostic companies. This strategy is aimed at advancing personalized medicine programs for cancer patients, thus broadening the company's impact in the oncology space.
With a commitment to transforming the cost, pace, and timeline of oncology drug discovery and development, Lantern Pharma continues to make strides in the development of precision therapies. The company's recent achievements and ongoing projects underscore its potential to revolutionize cancer treatment and deliver significant value to both patients and stakeholders.
Lantern Pharma Inc. (NASDAQ: LTRN) will host its third quarter 2022 financial results webcast on
Lantern Pharma (NASDAQ: LTRN) announced it will present new preclinical data at three scientific conferences: the Society of Neuro Oncology Annual Meeting on November 18, the San Antonio Breast Cancer Symposium on December 8, and the American Society of Hematology Annual Meeting on December 10. A key focus will be the preclinical efficacy of LP-184, a therapeutic targeting glioblastoma. Lantern Pharma leverages its proprietary RADR® platform to identify patients likely to benefit from its targeted therapies, which could significantly enhance treatment outcomes.
Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company, announced its participation in the ThinkEquity Conference on October 26, 2022, in New York, NY. Lantern's CEO, Panna Sharma, is set to host an A.I. and Drug Development Panel at 10:00 a.m. ET, discussing the role of A.I. in enhancing oncology drug development. Lantern is scheduled to present at 1:00 p.m. ET, with a webcast available for viewers. The company aims to leverage its RADR® A.I. platform to optimize drug discovery and development timelines.
Lantern Pharma (NASDAQ: LTRN) has secured U.S. Patent No. 11,471,431 for its drug candidate LP-300, aimed at enhancing survival in cancer patients with overexpressed thioredoxin or glutaredoxin. This patent extends commercial protection until late 2032, fostering potential partnerships and new cancer treatment programs. LP-300 is currently in a Phase 2 clinical trial for relapsed non-small cell lung cancer (NSCLC) patients. The drug has previously shown significant survival improvements in clinical trials.
Lantern Pharma (NASDAQ:LTRN), a clinical-stage biopharmaceutical company, is set to present at the MicroCap Rodeo Windy City Roundup 2022 on October 12 at 11:00 a.m. ET. CEO Panna Sharma will lead the presentation, which will be live-streamed and available for replay. Lantern Pharma leverages its proprietary RADR® platform for oncology drug discovery, focusing on developing targeted therapeutics based on patient genomic profiles. Attendees can schedule one-on-one meetings with the management team throughout the event.
Lantern Pharma Inc. (NASDAQ: LTRN) announced it will present preclinical data on its drug candidate LP-284 for mantle cell lymphoma (MCL) at the SOHO Tenth Annual Meeting from Sept. 28 to Oct. 1, 2022. LP-284 has demonstrated strong anti-tumor potency in MCL and other non-Hodgkin's lymphomas, particularly against Ibrutinib and Bortezomib-resistant cell lines. The company plans to submit an IND for LP-284 in Q1 2023 and launch a Phase 1 clinical trial in Q2 2023, aiming to capitalize on a $200 million annual market.
Lantern Pharma (NASDAQ: LTRN) announced a virtual key opinion leader webinar on September 22, 2022, at 12:00 p.m. ET. The webinar will address challenges in drug development for pediatric cancers and feature Dr. Peter Houghton, an expert from Greehey Children's Cancer Research Institute. He will discuss disparities in pediatric cancer research and present preliminary results for drug candidates LP-184 and LP-284. Registration details are available, with a replay on Lantern's website from September 23, 2022.
Lantern Pharma Inc. (NASDAQ: LTRN) announced the presentation of positive preclinical data for its drug candidate LP-184 targeting pancreatic cancer at the AACR Special Conference from
Lantern Pharma Inc. (NASDAQ: LTRN) announces that CEO Panna Sharma will present at H.C. Wainwright’s 24th Annual Global Investment Conference from September 12-14, 2022, in New York, NY. Lantern Pharma utilizes its RADR® AI platform to enhance oncology drug discovery, focusing on genomically targeted therapeutics. The company is currently developing four drug candidates across nine tumor targets. Details on registration and webcasting are provided for interested investors.
FAQ
What is the current stock price of Lantern Pharma (LTRN)?
What is the market cap of Lantern Pharma (LTRN)?
What does Lantern Pharma Inc. specialize in?
What is the RADR platform?
How does Lantern Pharma's approach reduce drug development costs?
What is the company's strategy for growth?
How does Lantern Pharma use AI in drug development?
Who are the key collaborators with Lantern Pharma?
What are some of Lantern Pharma's recent achievements?
Why is precision medicine important in cancer treatment?
How does Lantern Pharma's strategy benefit cancer patients?
What is the significance of biomarker-based genetic screening?
